NEWSROOM

Farcast is extending its tumor microenvironment technology platform to incorporate peripheral markers from patient blood samples. The new TruBlood extension will launch in 2025.

Farcast to deliver the Keynote Opening Address “Unlocking Tumor-Immune Dynamics: How TruTumor Histoculture Reveals Head and Neck Cancer Responses to Checkpoint Therapy" during hubXchange’s West Coast Immuno-Oncology Xchange, on September 24th in San Francisco, California

TruTumor Biosignatures published in Nature Communications demonstrate accurate responder and resistor patient cohorts for the popular immunotherapy nivolumab

Farcast Biosciences and the University of West Florida have announced their intent to collaborate on an innovative research program to make cancer treatment more predictable for patients. Studies and research conducted in the program will aid the development of therapeutics, diagnostics or other treatment modalities for precision cancer medicine.

German TÜV NORD, one of the world's largest inspection, certification & testing organization issued the certification covering the TruTumor culturing, pathology, assaying and data generation technologies.

Farcast, a pioneer and leader in human tumor microdynamics research, having established its labs in Bengaluru in Southern India with head and neck squamous cell carcinoma, renal cell carcinoma and stomach adenocarcinoma is expanding the range of cancers to include breast, lung and gyn cancers.

Farcast presented data from a first of its kind study in 10 RCC patients whose tumors were treated with sunitinib and nivolumab using the hTMD platform

Today marks the beginning of a new era in the field of cancer diagnosis and precision medicine with the coming together of two leading organizations Crosscope Inc., a Silicon Valley-based leader and provider of Vendor Agnostic AI-enabled Digital Pathology Platform, and Farcast Bioscience LLC, a Florida based Company.